Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis
Launched by AKROS PHARMA INC. · Jun 15, 2016
Trial Information
Current as of June 04, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Subjects with end stage renal disease on hemodialysis
- • Post-dialysis body weight \>45.0 kg
- • BMI between 18.0 and 40.0 kg/m2 (inclusive)
- Exclusion Criteria:
- • Subjects with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2.0 × upper limit of normal (ULN), or total bilirubin \>1.5 × ULN at the Screening Visit
- • Subjects who have hepatobiliary disease or condition (such as biliary cirrhosis)
- • Subjects with positive test results for HBsAg (hepatitis B surface antigen), HCV antibody or HIV antibody
- • Subjects with known history of liver failure or liver surgery
- • Subjects with a history or current clinically significant chronic or acute blood loss
About Akros Pharma Inc.
Akros Pharma Inc. is a dedicated clinical research organization focused on advancing innovative therapeutic solutions across various therapeutic areas. With a commitment to improving patient outcomes, Akros Pharma specializes in the development and execution of clinical trials, leveraging cutting-edge technology and a team of experienced professionals. The company emphasizes collaboration with healthcare providers and stakeholders to ensure rigorous adherence to regulatory standards and ethical practices. Through its strategic approach, Akros Pharma aims to accelerate the drug development process while maintaining the highest quality of research and patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minneapolis, Minnesota, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials